Preeti leads the Business Development and Partnerships activities for the Therapeutic Platforms at LifeArc including the commercialisation of our monoclonal antibody discovery and humanisation platforms. She obtained her PhD in Biochemistry at the National Institute for Medical Research and has more than 20 years research experience working in a number of disease areas including neuroscience, oncology and ophthalmology with postdoctoral roles held within UCL, University of Cambridge and University of Oxford. She joined LifeArc 15 years ago working on both small molecule and biologics drug discovery programs. Preeti is an experienced project and portfolio manager where she managed LifeArc’s world-leading antibody humanisation portfolio, which has resulted in the development of five commercialized drugs, including Keytruda® and Leqembi® and also led LifeArc’s portfolio to generate fully human antibodies using transgenic platforms against a number of target classes across a wide range of disease areas for pre-clinical development. More recently, in her role as a Scientific Director leading the Biologics Discovery and Development team in LifeArc’s Therapeutic Translation Platform group she oversaw a team of 28 scientists based at our sites in Stevenage and the Francis Crick Institute who are dedicated to the successful delivery of high-quality biological therapeutics to support LifeArc’s Portfolio.
Preeti is a passionate scientist that thrives on the successful delivery of drug discovery programs to the clinic for the benefit of patient healthcare and has a track record of success with a number of publications, named inventor on four patents and has been a Board Observer for DJS antibodies which was recently acquired by Abbvie.
